Describe pap smear — its aetiology, clinical features and management.

Definition

The Papanicolaou (Pap) smear is an exfoliative cytology test used to screen for premalignant and malignant lesions of the cervix by examining cells shed from the transformation zone.

Technique

With the cervix exposed by a speculum, cells are scraped from the squamo-columnar junction using an Ayre's spatula and endocervical brush (or collected in liquid medium), smeared/fixed and stained by the Papanicolaou method.

Reporting (bethesda System)

• NILM — negative for intraepithelial lesion/malignancy.
• ASC-US / ASC-H — atypical squamous cells.
• LSIL and HSIL — low- and high-grade squamous intraepithelial lesions.
• Squamous-cell carcinoma / glandular abnormalities (AGC).

When and How Often

Screening starts at age 21 (or 3 years after first intercourse) and is repeated every 3 years (or with co-testing for HPV every 5 years). An abnormal smear is evaluated by colposcopy and biopsy.

Prerequisites and Limitations

The smear is best taken in the mid-cycle, avoiding menstruation; the woman should not have douched or used vaginal medication/intercourse for 24–48 hours, and active infection is treated first. It is a screening, not a diagnostic, test and has a false-negative rate (inadequate sampling, an endocervical lesion), so a positive result always needs colposcopy and biopsy for confirmation.

Advantages

It is simple, inexpensive, painless and performed in the out-patient clinic without anaesthesia, and detects disease in the long premalignant phase — making it ideal for mass screening.

Liquid-based Cytology & HPV Testing

Liquid-based cytology (LBC) gives fewer unsatisfactory smears and allows reflex HPV testing from the same vial. Visual inspection with acetic acid (VIA) and HPV-DNA testing are the other screening tools, the latter being highly sensitive and increasingly used as a primary or co-test.

A Note on WHY the Pap Smear Works So Well

A useful point is understanding why so crude a test — scraping cells off the cervix and looking at them — has reduced deaths from cervical cancer by up to 80% wherever it has been applied systematically. Its power comes not from its accuracy (a single smear misses a fair proportion of lesions) but from the biology of the disease it screens for. Cervical cancer is preceded by a precancerous phase lasting some 10–15 years, during which abnormal cells are continuously shed from the surface of an easily-accessible organ. This means that even a test of modest sensitivity, repeated at intervals over that long window, will catch the great majority of lesions eventually — and, crucially, will catch them while they are still confined to the epithelium and completely curable by simple outpatient treatment (cryotherapy or LEEP). The test therefore does not merely detect cancer early: it prevents cancer altogether, by finding and removing its precursor. This is what distinguishes it from most cancer screening. Understanding that the Pap smear's success rests on a long precancerous phase, an accessible organ and a curable precursor — and on being repeated — explains why coverage matters more than the perfection of any single smear.

Sampling the transformation zone is essential for validity.

• The Pap smear samples exfoliated cells from the transformation zone (the squamocolumnar junction — where cancer arises) with an Ayre's spatula or cytobrush.
• It detects the precursor (CIN/dysplasia), reported by the Bethesda system (ASCUS, LSIL, HSIL) — so it prevents cancer, not merely detects it.
• Its power comes from the long (10–15 year) precancerous phase — so repeated testing catches most lesions even though a single smear may miss some.
• Abnormal smear → colposcopy with directed biopsy → treat CIN (cryotherapy, LEEP, conisation).
• In India, VIA (visual inspection with acetic acid) and HPV DNA testing are used where cytology is not feasible — coverage matters more than the test.